H.C. Wainwright reiterates USD 80.00 target for CRISPR Therapeutics stock

Published on 10/20/2026 at 22:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The Nasdaq quote was USD 49.88 after hours on October 20, 2026 in US trading. CRISPR Therapeutics stock costs EUR 44.46 on October 20, 2026.

Analyst target and reporting date

H.C. Wainwright reiterated a USD 80.00 target for CRISPR Therapeutics on October 9, 2026.
The USD 80.00 target stood 60.39 percent above the USD 49.88 Nasdaq quote on October 20, 2026.
CRISPR Therapeutics stock cost EUR 44.46 at Lang & Schwarz on October 20, 2026 at 10:00 p.m. CEST.
Q3 2026 results are estimated for November 9, 2026.

CRSP, CH0334081137, Illustration mit AI erstellt.

CRISPR Therapeutics (ISIN CH0334081137) received a reiterated USD 80.00 price target from H.C. Wainwright on October 9, 2026, while the Nasdaq quote stood at USD 49.88 on October 20, 2026. According to Investing.com, the firm maintained its Buy rating and USD 80.00 target. The EUR quote was EUR 44.46 at Lang & Schwarz on October 20, 2026 at 10:00 p.m. CEST.

The target gap remains wide

Using the Nasdaq quote of USD 49.88 at 4:00 p.m. ET on October 20, 2026, the USD 80.00 target was 60.39 percent above the stock price. H.C. Wainwright also cited CTX310 data as part of its assessment, with the program focused on ANGPTL3 editing for severe hypertriglyceridemia, according to Investing.com.

Revenue and pipeline dates

CRISPR Therapeutics reported USD 10.18 million of revenue and an adjusted loss of USD 0.94 per share for the second quarter of 2026. The figures are reported on the company profile maintained by MarketBeat. The company site lists an October 8, 2026 release about late-breaking data at the American Heart Association Scientific Sessions, according to CRISPR Therapeutics.

What comes next for results?

MarketBeat estimates that CRISPR Therapeutics will report third-quarter 2026 results on November 9, 2026, after the market closes, with a conference call scheduled for November 3, 2026 at 4:00 p.m. ET. The same estimate calls for USD 14.75 million of revenue and a loss of USD 1.04 per share, versus USD 0.89 million of revenue and a loss of USD 1.17 per share in the year-earlier quarter, according to MarketBeat.

Price and market position

CRISPR Therapeutics had a market capitalization of USD 4.8 billion and a 52-week Nasdaq range of USD 44.12 to USD 75.06 on October 20, 2026. Editas Medicine had a USD 396.2 million market capitalization and Intellia Therapeutics had USD 1.7 billion, placing CRISPR Therapeutics above both gene-editing peers by that measure.

Stock stays in a broad range

The EUR quote at Lang & Schwarz was EUR 44.46 on October 20, 2026 at 10:00 p.m. CEST. The US listing was identified as Nasdaq: CRSP, with the company classified in biotechnology.

The further course of trading is shown by the continuously updated real-time quote of CRISPR Therapeutics stock.